SHL:XETRA-Siemens Healthineers AG (EUR)

COMMON STOCK | Medical Devices | XETRA

Last Closing Price

EUR 59.56

Change

-0.02 (-0.03)%

Market Cap

EUR 67.23B

Volume

0.41M

Avg Analyst Target

EUR 61.92 (+3.97%)

Avg User Target

EUR
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


Siemens Healthineers AG (SHL) Stock Analysis:
Based on the Siemens Healthineers AG stock forecasts from 9 analysts, the average analyst target price for Siemens Healthineers AG is EUR 61.92 over the next 12 months. Siemens Healthineers AG’s average analyst rating is . Stock Target Advisor’s own stock analysis of Siemens Healthineers AG is Slightly Bearish, which is based on 5 positive signals and 7 negative signals. At the last closing, Siemens Healthineers AG’s stock price was EUR 59.56. Siemens Healthineers AG’s stock price has changed by -1.42% over the past week, -4.40% over the past month and +37.52% over the last year.

About

Siemens Healthineers AG, through its subsidiaries, develops, manufactures, and sells a range of diagnostic and therapeutic products and services to healthcare providers worldwide. The company operates through four segments: Imaging, Diagnostics, Varian, and Advanced Therapies. Th ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-17 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ABL:XETRA Abbott Laboratories

+1.65 (+1.48%)

EUR197.82B 31.63 17.69
2M6:XETRA Medtronic plc

+0.66 (+0.70%)

EUR128.29B 31.29 17.56
SYK:XETRA Stryker Corporation

+7.20 (+3.13%)

EUR90.58B 54.46 26.55
PHI1:XETRA Koninklijke Philips N.V

-0.31 (-1.02%)

EUR26.48B 7.27 26.67
EUZ:XETRA Eckert & Ziegler Strahlen- und..

+1.00 (+1.23%)

EUR1.69B 48.98 33.13
SBS:XETRA Stratec SE

+2.00 (+1.69%)

EUR1.43B 31.05 22.49
DRW3:XETRA Drägerwerk AG & Co. KGaA

+0.45 (+0.88%)

EUR1.05B 4.31 1.99
DRW8:XETRA Drägerwerk AG & Co. KGaA

N/A

EUR1.04B 4.27 1.99
PSH:XETRA Sernova Corp

+0.04 (+3.37%)

EUR0.40B N/A N/A
MF6:XETRA MagForce AG

-0.06 (-2.13%)

EUR0.08B 5.70 6.09

ETFs Containing SHL

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -9.51% 36% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.51% 36% F 5% F
Trailing 12 Months  
Capital Gain 37.52% 92% A- 88% B+
Dividend Return 1.85% 70% C- 45% F
Total Return 39.37% 92% A- 88% B+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 12.29% 85% B 70% C-
Dividend Return 0.60% 45% F 21% F
Total Return 12.89% 85% B 71% C-
Risk Return Profile  
Volatility (Standard Deviation) 19.55% 62% D- 39% F
Risk Adjusted Return 65.93% 54% F 70% C-
Market Capitalization 67.23B 79% C+ 94% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 37.96 27% F 29% F
Price/Book Ratio 4.95 46% F 26% F
Price / Cash Flow Ratio 22.92 38% F 21% F
EV/EBITDA 21.39 45% F 21% F
Management Effectiveness  
Return on Equity 12.10% 46% F 54% F
Return on Invested Capital 13.20% 71% C- 80% B-
Return on Assets 4.75% 50% F 63% D
Debt to Equity Ratio 0.12% 85% B 96% A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.38 57% F 92% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.